Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Company Deals

China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio

Fineline Cube Apr 27, 2026
Company Deals

Johnson & Johnson Acquires Atraverse Medical to Expand Cardiac Ablation Portfolio with Next-Gen Left-Heart Access Technology

Fineline Cube Apr 27, 2026
Company Deals

Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider

Fineline Cube Apr 24, 2026
Company Deals

Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market

Fineline Cube Apr 24, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Sanofi Secures CHMP Positive Opinion for Cenrifki (Tolebrutinib) in Non-Relapsing SPMS Despite FDA Complete Response Letter Setback

Fineline Cube Apr 27, 2026
Company Drug

Novartis Withdraws Pluvicto Pre-Chemotherapy mCRPC Application in EU Following CHMP Objections on PSMAfore Control Arm Design

Fineline Cube Apr 27, 2026
Company Drug

Roche Subsidiary Genentech Addresses Accidental Disclosure of Tiragolumab Trial Data

Fineline Cube Aug 23, 2023

Swiss pharmaceutical major Roche (SWX: ROG), through its subsidiary Genentech, has released a statement addressing...

Policy / Regulatory

Shanghai Updates Biomedical R&D Import Pilot for Streamlined Customs Clearance

Fineline Cube Aug 23, 2023

The Shanghai Municipal Commission of Commerce, in collaboration with Shanghai Customs and the Shanghai Municipal...

Company Deals

Bayer Partners with Mahana Therapeutics to Market Digital Health Technologies

Fineline Cube Aug 23, 2023

Germany-headquartered Bayer (ETR: BAYN) has announced a strategic partnership with US digital developer Mahana Therapeutics....

Company Drug

European Commission Grants Conditional Approval for Janssen’s Talvey in Multiple Myeloma

Fineline Cube Aug 23, 2023

The European Commission (EC) has granted conditional approval to Johnson & Johnson’s (J&J; NYSE: JNJ)...

Company Drug

Jiangsu Hengrui Pharmaceuticals’ Fluzoparib Files for New Indication with China’s NMPA

Fineline Cube Aug 23, 2023

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that the National Medical Products...

Company Drug

Kintor Pharmaceutical Completes Enrollment in Phase II Study of GT20029 for Androgenetic Alopecia

Fineline Cube Aug 23, 2023

China-based Kintor Pharmaceutical Limited (HKG: 9939) has announced the completion of patient enrollment in a...

Company Drug

Novartis’s Leqvio (Inclisiran) Approved in China for Hypercholesterolemia Treatment

Fineline Cube Aug 23, 2023

Swiss pharmaceutical giant Novartis (NYSE: NVS) has received approval from the National Medical Products Administration...

Company Drug

Novatim’s KQ-2003 and KY-0118 Advance with Clinical Trial Approvals in China

Fineline Cube Aug 22, 2023

China-based cancer immunotherapy specialist Novatim Immune Therapeutics (Zhejiang) Co., Ltd has recently obtained clinical trial...

Company Drug

Sichuan Huiyu Pharmaceutical’s Plerixafor Gains Marketing Approval from Italian Medicines Agency

Fineline Cube Aug 22, 2023

Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a China-based pharmaceutical company, has announced that it...

Company Medical Device

Lifetech Scientific Corporation Receives NMPA Approval for Epione Navigation System

Fineline Cube Aug 22, 2023

China-based Lifetech Scientific Corporation (HKG: 1302) has announced that it has received market approval from...

Company Deals

Jiahui Health and Gleneagles Hong Kong Hospital Partner for Integrated Healthcare Services

Fineline Cube Aug 22, 2023

China-based Jiahui Health has entered into a strategic partnership with Gleneagles Hong Kong Hospital to...

Company Deals

Saints Sages Surgical Secures Series B Funding to Advance Energy-Based Devices

Fineline Cube Aug 22, 2023

Shanghai-based Saints Sages Surgical Co., Ltd, a leading developer of high-value minimally invasive surgical products,...

Company Drug

Hainan Huluwa Pharmaceutical Gets NMPA Approval for Generic Briviact Clinical Study

Fineline Cube Aug 22, 2023

China-based Hainan Huluwa Pharmaceutical Group Co., Ltd (SHA: 605199) has announced that it has received...

Company Deals

CSPC Pharmaceutical Group Partners with Insilico and XtalPi for AI-Driven Drug R&D

Fineline Cube Aug 22, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced strategic partnership agreements with Insilico Medicine...

Company Drug

Luye Pharma Group Submits Market Approval Filing for Lurbinectedin in Metastatic SCLC in Macau

Fineline Cube Aug 22, 2023

China-based Luye Pharma Group (HKG: 2186) has announced that a market approval filing has been...

Company Medical Device

magAssist Receives FDA Breakthrough Device Designation for NyokAssist VAD

Fineline Cube Aug 22, 2023

magAssist, a firm based in Suzhou, China, has announced that it has received breakthrough device...

Company Drug

Auzone Biological Technology Gets FDA Approval for Edaravone Oral Preparations in ALS

Fineline Cube Aug 22, 2023

Suzhou Auzone Biological Technology Co., Ltd. has received approval from the US Food and Drug...

Company

RemeGen Ltd Reports 20.56% YOY Revenue Growth in H1 2023 Financial Results

Fineline Cube Aug 22, 2023

China-based RemeGen Ltd (SHA: 688331, HKG: 9995) has released its financial report for the first...

Company Drug

Gilead’s Magrolimab Phase III Trial for AML Faces Partial Hold by FDA

Fineline Cube Aug 22, 2023

Gilead (NASDAQ: GILD) has announced that the US Food and Drug Administration (FDA) has imposed...

Company

Ascentage Pharma’s 2023 Interim Report: 49% YOY Revenue Growth and Market Expansion

Fineline Cube Aug 22, 2023

China-based Ascentage Pharma (HKG: 6855) has released its 2023 interim financial report, revealing a 49%...

Posts pagination

1 … 476 477 478 … 657

Recent updates

  • Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets
  • Boehringer Ingelheim Launches Pulmonary Fibrosis Care Initiative in China with CNR News, Tencent Medipedia, and Patient Groups to Combat Underdiagnosed Fatal Lung Disease
  • Sanofi Secures CHMP Positive Opinion for Cenrifki (Tolebrutinib) in Non-Relapsing SPMS Despite FDA Complete Response Letter Setback
  • China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio
  • Novartis Withdraws Pluvicto Pre-Chemotherapy mCRPC Application in EU Following CHMP Objections on PSMAfore Control Arm Design
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Company

Boehringer Ingelheim Launches Pulmonary Fibrosis Care Initiative in China with CNR News, Tencent Medipedia, and Patient Groups to Combat Underdiagnosed Fatal Lung Disease

Company Drug

Sanofi Secures CHMP Positive Opinion for Cenrifki (Tolebrutinib) in Non-Relapsing SPMS Despite FDA Complete Response Letter Setback

Company Deals

China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.